Clinical trialNCT03429803CompletedPhase 1Interventional

DAY101 In Gliomas and Other Tumors

SponsorKaren D. Wright, MDEnrollment44Low-grade Glioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Karen D. Wright, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Children'S National Hospital
Washington D.C., District of Columbia, United States
University of Florida
Gainesville, Florida, United States
Johns Hopkins University
Baltimore, Maryland, United States
Boston Children'S Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institite
Boston, Massachusetts, United States
Massacusetts General Hospital
Boston, Massachusetts, United States
Children'S Minnesota
Minneapolis, Minnesota, United States
Washington University in St. Louis
St Louis, Missouri, United States
Oregon Health & Science University
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DAY101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Feb 2018
Primary completion: 31 Dec 2025
Completion: 31 Dec 2025
Last update posted: 19 Feb 2026
Registered enrollment: 44
Registry id: NCT03429803

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.